COMMUNIQUÉS West-GlobeNewswire
-
Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit
22/06/2026 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2026
22/06/2026 -
Genista Launches Refreshed Brand and Website, Positioning Itself as the Operating System for Product Safety
22/06/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
22/06/2026 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026
22/06/2026 -
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
22/06/2026 -
Novel Key Terms For Managing CIDP Published in Neurology® Journal
22/06/2026 -
BrewDog Bars Draw Record Fan Turnout as Global Tournament Fever Drives Double-Digit Growth
22/06/2026 -
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
22/06/2026 -
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
22/06/2026 -
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
22/06/2026 -
St. Augustine Dentist Explains Why Replacing Missing Teeth Can Support Long-Term Oral Health
22/06/2026 -
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
22/06/2026 -
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
22/06/2026 -
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026 -
Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis
22/06/2026 -
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
22/06/2026 -
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
22/06/2026 -
Route 92 Medical Announces First Commercial Cases in Canada
22/06/2026
Pages